These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32690263)

  • 1. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1' ligands.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Future Med Chem; 2020 May; 12(9):775-794. PubMed ID: 32125179
    [No Abstract]   [Full Text] [Related]  

  • 3. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
    Zhou H; Zhu M; Ma L; Zhou J; Dong B; Zhang G; Cen S; Wang Y; Wang J
    PLoS One; 2020; 15(7):e0235483. PubMed ID: 32697773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
    Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
    Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
    Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
    Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
    Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdependence of Inhibitor Recognition in HIV-1 Protease.
    Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Leshchenko-Yashchuk S; Anderson DD; Baldridge A; Noetzel M; Miller HB; Tie Y; Wang YF; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2009 Jul; 52(13):3902-14. PubMed ID: 19473017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants.
    Hu S; Ma L; Dong B; Shan Q; Zhou J; Zhang G; Wang M; Cen S; Zhu M; Wang J; Wang Y
    Bioorg Med Chem; 2022 Jun; 64():116760. PubMed ID: 35483138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
    Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.